SpaceX Hires Natural Gas Trader to Meet Growing Energy Needs 
Nordson Stock Rises as Q3 Earnings Beat Estimates, Outlook Raised 
OpenAI Revenue Rises 18% in Q2 as Losses Widen and Anthropic Surges Ahead 
Baidu Shares Sink to One-Year Low as Ad Weakness Overshadows AI Growth 
Samsung Eyes $72 Billion Shareholder Return Plan as AI Chip Boom Fuels Profits 
Nvidia AI Server Prices Set to Rise as Memory Costs Surge 
Barclays Downgrades Renault as Cost Savings Challenges Grow 
OpenAI Tightens AI Safety Monitoring After Security Incidents 
Welspun Corp Shares Hit Record High on $1.8 Billion U.S. Order 
Unifor Reaches Tentative GM Deal for 4,600 Ontario Workers 
Apple Cuts Over 200 Siri, Vision Pro Jobs in AI Shift 
REPAY Stock Rises After Visa Platform Connect Collaboration 
CK Hutchison Seeks $1.5 Billion From Panama Over Canal Ports 
SEC Sues Former Tricolor Executives Over $1.9 Billion Investor Fraud Scheme 
Unitree Robotics Shares Soar Over 600% in Shanghai Market Debut 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
Goldman Sachs Names 9 Top Japanese Semiconductor and Electronics Stocks 
Add as a preferred source on Google
ALAMEDA, Calif, May 08, 2018 -- OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive liquid biopsy tests for the early detection of cancer, announced today that it will release its financial and operating results for the first quarter of 2018, ended March 31, 2018, on Tuesday, May 15, 2018, after the close of the U.S. financial markets. The Company will host a conference call on Tuesday, May 15, 2018, at 4:30 pm ET / 1:30 pm PT to discuss the results along with recent corporate developments.
The dial-in number in the U.S./Canada is 800-263-0877; for international participants, the number is +1-323-794-2094. For all callers, please refer to Conference ID 6365614. To access the live webcast, go to the investor relations section on the Company’s website, http://investors.oncocyte.com/events-and-presentations.
A replay of the conference call will be available for seven business days beginning about two hours after the conclusion of the live call, by calling 888-203-1112 toll-free (from U.S./Canada); international callers dial 719-457-0820. Use the Conference ID 6365614. Additionally, the archived webcast will be available at http://investors.oncocyte.com/events-and-presentations.
About OncoCyte Corporation
OncoCyte is focused on the development and commercialization of novel, non-invasive blood and urine (“liquid biopsy”) diagnostic tests for the early detection of cancer. Early detection of cancer can improve health outcomes, reduce the cost of care, and improve patients’ quality of life. Liquid biopsy diagnostic tests like those OncoCyte is developing may reduce the need for costlier and riskier diagnostic procedures such as invasive biopsy and cystoscopic procedures. OncoCyte’s development pipeline is focused on non-invasive confirmatory diagnostic tests for lung, breast, and bladder cancer. OncoCyte’s tests are being developed using proprietary sets of genetic and protein molecular markers that differentially express in specific types of cancer. OncoCyte conducts ongoing research to identify additional molecular markers, acquire or license markers and related technology, and develop tests based on those markers.
Contact
EVC Group LLC
Matt Haines / Michael Polyviou
917-733-9297 / 732-933-2754
[email protected] / [email protected]
